NWBO (Northwest Biotherapeutics) Other Long-Term Liabilities: $12.10 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NWBO Northwest Biotherapeutics Inc NWBO
11 GF Score
Price $0.17
! 6 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Other Long-Term Liabilities?

Northwest Biotherapeutics NWBO +0.49% 11 Other Long-Term Liabilities is $12.10 Mil as of Jun. 2026. GuruFocus rates NWBO with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

Northwest Biotherapeutics's other long-term liabilities for the quarter that ended in Jun. 2026 was $12.10 Mil.

Northwest Biotherapeutics's quarterly other long-term liabilities declined from Dec. 2025 ($14.41 Mil) to Mar. 2026 ($14.18 Mil) and declined from Mar. 2026 ($14.18 Mil) to Jun. 2026 ($12.10 Mil).

Northwest Biotherapeutics's annual other long-term liabilities declined from Dec. 2023 ($23.67 Mil) to Dec. 2024 ($20.21 Mil) and declined from Dec. 2024 ($20.21 Mil) to Dec. 2025 ($14.41 Mil).

Northwest Biotherapeutics Other Long-Term Liabilities Related Terms

Northwest Biotherapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics Other Long-Term Liabilities Chart

Northwest Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 23.06 23.67 20.21 14.41

Northwest Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.45 15.10 14.41 14.18 12.10
NWBO
11GF Score
Northwest Biotherapeutics Inc NWBO
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Northwest Biotherapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $12.10 Mil mean?
Northwest Biotherapeutics (NWBO) has a Other Long-Term Liabilities of $12.10 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Northwest Biotherapeutics and its competitors.
Is Northwest Biotherapeutics' Other Long-Term Liabilities too high?
Northwest Biotherapeutics' current Other Long-Term Liabilities is $12.10 Mil. Overall, Northwest Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Other Long-Term Liabilities compare to PRQR and IMRX?
Northwest Biotherapeutics' Other Long-Term Liabilities of $12.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current Other Long-Term Liabilities is $12.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Northwest Biotherapeutics (NWBO) has a current Other Long-Term Liabilities of $12.10 Mil. The current Other Long-Term Liabilities is $12.10 Mil. Northwest Biotherapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current Other Long-Term Liabilities is $12.10 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Northwest Biotherapeutics Business Description

Other Exchanges NBYB:Germany
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
11GF Score

Get the complete analysis for NWBO

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price